Normal view MARC view

New fluoroquinolones in lower respiratory tract infections and emerging patterns of pneumococcal resistance [Article de Revue]

 
[Nouvelles fluoroquinolones dans les infections respiratoires basses et émergence de profils de résistance des pneumocoques]
FERRARA AM
Infection. 2005/06; 33(3) : 106-114
Summary: L'augmentation de la résistance de Streptococcus pneumoniae aux bêta lactams et à d'autres antibiotiques utilisés pour le traitement empirique des infections respiratoires basses a conduit à recommander l'usage d'une fluoroquinolone pour traiter ces infections. Les caractéristiques microbiologiques, pharmacocinétiques et pharmacodynamiques des nouvelles fluoroquinolones (levofloxacine, moxifloxacine, gemifloxacine et gatifloxacine) ont encouragé leur usage et probablement contribué à l'émergence de pneumocoques résistants aux fluoroquinolones. Des échecs de traitement par levofloxacine ont été rapportés dans la prise en charge de patients présentant une pneumonie à peumocoque d'origine communautaire. Un usage ciblé des fluoroquinolones devraît maintenir l'efficacité de cette classe d'antibiotiques. (RESUME D'AUTEUR)

The increasing resistance of Streptococcus pneumoniae, the most important community respiratory pathogen, to beta-lactams and other first-line antimicrobial agents usually employed for the empirical treatment of lower respiratory tract infections has led to the inclusion, in several current guidelines, of a fluoroquinolone with improved activity against pneumococci as the first choice agent for the management of such infections. The excellent microbiological, pharmacokinetic, and pharmacodynamic characteristics of the new fluoroquinolones (levofloxacin, moxifloxacin, gemifloxacin, and gatifloxacin) have encouraged their growing use, probably contributing to the emergence of fluoroquinolone-resistant pneumococci; although pneumococcal resistance to new fluoroquinolones is currently low, there is still concern about the potential for widespread emergence of resistance to these agents if they become indiscriminately used. Levofloxacin clinical failures have already been reported in the management of patients with pneumococcal community-acquired pneumonia; development of resistance in clinical isolates of S. pneumoniae has prompted a critical reexamination of the newer fluoroquinolones to assess their potency and to preserve their activity. An understanding of the pharmacokinetic and pharmacodynamic properties, allowing selection of the most potent fluoroquinolone, will reduce the opportunity for resistance to develop. Finally, a targeted use of these agents will maintain class efficacy.(RESUME D'AUTEUR)
Publication
2005/06

Pages
106-114

Language
Anglais

Number of ref
98

Published in
Infection

ID notice
318938

Location Call number Status Date due Barcode
CCLIN Est
CClin Est
CHU de Nancy - Hôpitaux de Brabois
Rue du Morvan
54511 Vandoeuvre le Nancy Cedex
Tél : 03.83.15.34.73
cclin.est@chu-nancy.fr
http://www.cclin-est.org/
CCLIN Ouest
CClin Ouest
CHU Hôtel Dieu
CS 26419
35064 Rennes Cedex 2
Tél : 02.99.87.35.31
isabelle.girot@chu-rennes.fr
http://www.cclinouest.com/
CCLIN Paris Nord
CClin Paris-Nord
96 rue Didot
75014 Paris
Tél : 01.40.27.42.00  
karin.lebascle@sap.aphp.fr
http://www.cclinparisnord.org/
CCLIN Sud-Est
CClin Sud-Est
Hospices Civils de Lyon
Hôpital Henry Gabriel
20 route de vourles
69230 Saint-Genis-Laval
Tél : 04.78.86.49.50
cclinse@chu-lyon.fr
http://cclin-sudest.chu-lyon.fr/
CCLIN Sud-Ouest
CClin Sud-Ouest
CHU de Bordeaux
Hôpital Pellegrin - Bâtiment Le Tondu
33076 Bordeaux
Tél : 05.56.79.60.58
cclin.so@chu-bordeaux.fr
http://www.cclin-sudouest.com/

There are no comments for this item.

Log in to your account to post a comment.
Tags from this library:
No tags from this library for this title.
Log in to add tags.
    average rating: 0.0 (0 votes)
Languages: